Outcome of Surgical Treatment for Metastatic Spinal Cord Compression: A Single-Center Retrospective Study
- PMID: 36570752
- PMCID: PMC9771617
- DOI: 10.1055/s-0042-1758846
Outcome of Surgical Treatment for Metastatic Spinal Cord Compression: A Single-Center Retrospective Study
Abstract
Objective The spinal column is one of the most prevalent regions for metastasis, with an increasing frequency of spinal metastases. Spinal cord metastatic tumor damages the vertebral body, weakens the spinal support, and exerts mass effect on the spinal cord. Overzealous surgical intervention does not provide any additional benefit in most of the spinal metastasis due to shorter life expectancy. The principal goal of this study is to analyze the outcome of various surgical treatments offered to patients with metastatic spinal cord compression (MSCC). Methods Retrospective cohort study including all patients that underwent surgical intervention for MSCC from March 2013 to March 2020. Results A total of 198 patients were included, 113 males and 85 females; the mean age was 62 years. The most common primary cancer was prostate (21.71%) followed by hematological (20.07%) and lung (16.66%). At 6-month postsurgery, 68.68% of patients were Frankel grade D or E (vs. 23.23% preoperatively), 16.6% were grade C (vs 57% preoperatively), and 14.64% were grade A or B (vs. 19.69% preoperatively). Pain on numeric rating scale was decreased from 6.38 ± 3.08 to 3.39 ± 0.73 at 24 hours postsurgery and 1.94 ± 0.67 at 6 months. Conclusion This study found that the majority of patients, undergoing minimally invasive spinal stabilization and decompression for metastatic spinal tumors, have better quality of life, analgesia, and mobility. In conclusion, treatment for spinal metastases should be individualized and a multidisciplinary approach is needed.
Keywords: metastatic spinal cord compression (MSCC); minimally invasive spine (MIS) surgery; spinal cord metastatic tumor; spinal metastasis.
Asian Congress of Neurological Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).
Conflict of interest statement
Conflict of Interest None declared.
Figures
References
-
- Choi D, Bilsky M, Fehlings M, Fisher C, Gokaslan Z.Spine oncology-metastatic spine tumors Neurosurgery 201780(3S):S131–S137. - PubMed
-
- Rosen L S, Gordon D, Kaminski M. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98(08):1735–1744. - PubMed
-
- Lutz S, Lo S S, Chow E, Sahgal A, Hoskin P. Radiotherapy for metastatic bone disease: current standards and future prospectus. Expert Rev Anticancer Ther. 2010;10(05):683–695. - PubMed
-
- Patchell R A, Tibbs P A, Regine W F.Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial Lancet 2005366(9486):643–648. - PubMed
LinkOut - more resources
Full Text Sources